Anixa Biosciences Completes Treatment of Fifth Cohort in Ovarian Cancer CAR-T Trial
The company said the first patient in the fifth cohort had stable disease 90 days after treatment. Multiple patients have survived more than one year, including one beyond two years, with no dose-limiting toxicities observed to date. The cohort received 1×10⁷ CAR-positive cells/kg following lymphodepletion.
Story updates
12:31:21 PM UTC
SquawkNews
Anixa completed dosing of the fifth cohort in its Phase 1 FSHR—targeted CAR—T trial for recurrent ovarian cancer, reporting no dose—limiting toxicities to date and stable disease at 90 days in the first patient of the cohort. Four patients have survived beyond one year, one beyond two years.Materia…